PDEX
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Pro-Dex, Inc. is a vertically integrated contract manufacturer and product development company specializing in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers. The company serves the orthopedic, thoracic, and craniomaxillofacial markets, providing patented adaptive torque-limiting technology and proprietary sealing solutions to medical device distributors and original equipment manufacturers. Pro-Dex also offers engineering, quality, and regulatory consulting services, as well as repair services for its medical devices. Through its subsidiary Advanced Precision Machining, LLC, the company manufactures precision machined parts and assemblies for the aerospace and defense industries, holding ITAR and Joint Certification Program registrations. Additionally, Pro-Dex produces rotary air motors for various industrial applications. The company was incorporated in 1994 and operates facilities in Irvine and Tustin, California, with a second machine shop in Costa Mesa, California.

Summarised from the company's own disclosures, fiscal year ended Sep 2026

Industry Medical Devices Homepage pro-dex.com
Sector Healthcare IR page pro-dex.com/investors
Tags
surgical drivers, surgical shavers, orthopedic devices, craniomaxillofacial devices, contract manufacturing, precision machining, aerospace parts, defense parts, rotary air motors, medical device repair, regulatory consulting, adaptive torque-limiting technology, Advanced Precision Machining LLC, APM, PDEX Franklin LLC
Press page —

Metrics

Valuation  
Market cap $ 221.03M
Market cap (USD) $ 221.03M
P/E 18.96
PEG 0.77
P/BV 4.48
P/S 2.78
P/OCF 19.35
P/FCF 20.67
Dividend yield —
Turnover / mcap —
Returns  
ROE 32.4%
ROI 21.0%
ROIC 15.1%
Profit margin 17.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 24.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 36.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Revenue 77.548M 66.593M 53.844M 46.087M 42.041M 38.029M 34.834M 27.172M 22.465M 21.943M 20.158M 13.383M 10.812M 722K 17.257M 24.06M 21.122M 25.126M
Net profit 13.662M 8.978M 2.127M 7.074M 3.855M 4.45M 6.112M 4.148M 1.621M 5.084M 822K -365K -488K -1.784M -876K 2.64M -2.845M 317K
Free cash flow 6.759M -2.928M 5.241M 4.488M -2.485M -3.847M 4.426M 1.939M 2.173M 2.629M 155K -1.019M -379K -1.357M -296K 2.633M 1.449M -1.112M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Share price 58.55 43.64 19.64 19.1 15.95 30.56 17.82 12.98 6.67 6.12 5.57 2.33 2.1 1.9 2.19 — 0.42 1.07
Price performance 12m 0.34 1.22 0.03 0.2 -0.48 0.71 0.37 0.95 0.09 0.1 1.39 0.11 0.11 -0.13 — — -0.61 -0.31

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 3.54M 2.96M 4.1M 5.16M 10.9M 15.4M 9.95M 13.9M 16.4M 21.2M
↳ YoY growth +140.8% -16.5% +38.7% +25.7% +112.1% +40.7% -35.3% +39.5% +18.3% +29.0%
↳ 5y CAGR +17.5% +17.2% +18.2% +17.3% +49.4% +34.2% +27.5% +27.6% +26.1% +14.2%
Borrowings, current (USD) 58,000 35,000 622,000 651,000 1.24M — — — — —
Borrowings, non-current (USD) 61,000 6,000 3.93M 3.28M 11.5M — — — — —
Lease liabilities (USD) — — 3.3M 2.75M 2.43M 2.43M 1.64M 1.18M 685,000 627,000
Cash and deposits (USD) 4.21M 5.19M 7.74M 6.42M 3.72M 849,000 2.94M 2.63M 419,000 8.19M
Intangible assets (USD) 320,000 140,000 129,000 162,000 186,000 118,000 81,000 54,000 26,000 686,000
Right-of-use assets (USD) — — 3.3M 2.94M 2.61M 2.25M 1.87M 1.47M 1.05M 602,000
Net debt (borrowings + leases - cash) (USD) -4.14M -5.15M -3.19M 263,000 11.5M — — — — —
Cash flow detail
Operating cash flow (USD) 3.24M 3.1M 3.33M 4.95M -2.08M -847,000 5.46M 6.2M -1.68M 7.24M
Purchases of property, plant and equipment (USD) -606,000 -923,000 -1.39M -519,000 -1.77M -1.64M — — -1.25M -483,000
Purchases of intangible assets (USD) -32,000 -11,000 -11,000 -46,000 -38,000 -33,000 — — — —
Change in receivables (cash effect) (USD) -633,000 569,000 -1.13M -1.06M -5.78M -4.45M 5.43M -3.94M -2.55M -4.71M
Change in inventories (cash effect) (USD) 279,000 -1.31M -1.85M -2M -199,000 -4.24M -3.49M 898,000 -6.94M 1.63M
Change in payables (cash effect) (USD) — — — — 105,000 1.99M -1.15M 2.44M 179,000 -12,000
Share buybacks (cash effect) (USD) -312,000 -220,000 -3.98M -3.39M -5.54M -1.61M -1.55M -3.51M -3.5M -3.41M
Interest paid (cash effect) (USD) -12,000 -7,000 -199,000 -218,000 -330,000 -463,000 -521,000 -555,000 -818,000 -775,000
Income taxes paid (cash effect) (USD) -217,000 -401,000 -320,000 -683,000 -1.77M -1.57M -1.66M -1.89M -4.46M -4.11M
Share-based compensation (USD) 3,000 194,000 37,000 286,000 901,000 1.28M 766,000 605,000 555,000 688,000
Operating cash flow before change in receivables (USD) 3.87M 2.53M 4.46M 6.01M 3.71M 3.6M 30,000 10.1M 864,000 12M
Free cash flow (OCF - PPE - intangibles) (USD) 2.6M 2.16M 1.93M 4.38M -3.89M -2.52M — — -2.93M 6.76M
Income detail
Research and development expense (USD) 1.23M 1.89M 1.88M 2.32M 4.38M 2.98M 2.8M 3.19M 3.64M 3.35M
↳ 5y CAGR -9.9% +1.1% +4.9% +6.8% +18.8% +19.5% +8.2% +11.1% +9.4% -5.3%
Total comprehensive income (USD) 5.12M 1.44M 3.75M 5.08M 5.82M — — — — —
Comprehensive income to owners (USD) 5.12M 1.44M 3.75M 5.08M 5.82M — — — — —
Provision for credit losses (USD) -17,000 14,000 -14,000 6,000 5,000 -2,000 — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.7% 0.4% 0.4% 0.1% 0.1% 0.0% — — — —
Reported Feb 8, 2018 Nov 8, 2018 Feb 6, 2020 Sep 10, 2020 Sep 8, 2022 Sep 8, 2022 Oct 13, 2023 Sep 5, 2024 Sep 3, 2026 Sep 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

UMB Amendment No. 1 to Second Amended and Restated Credit & Security Agreement

As previously disclosed, on February 9, 2026, Pro-Dex, Inc. (the “Company”) entered into a Second Amended and Restated Credit and Security Agreement (the “Amended Credit Agreement”) with UMB Bank, N.A. (“UMB”). On November 11, 2026 (the “Credit Amendment Date”), the Company and its wholly owned subsidiary Advanced Precision Machining, LLC (as guarantor) entered into Amendment No. 1 to Second Amended and Restated Credit and Security Agreement (“Amendment No. 1”) with UMB, which consolidated the outstanding principal balances of Term Note C and Term Note D in the amount of $8,513,333.16 pursuant to an Amended and Restated Term Note D (“Term Note D”) thereby extinguishing Term Note C, extending the maturity date of Term Note D from February 1, 2031 to November 1, 2031, providing for a fixed interest rate on Term Note D of 6.67% per annum, modifying the monthly payment due on Term Note D to an amount necessary to fully amortize the outstanding principal balance of Term Note D over a period of 60 months commencing on December 1, 2026, and extending the maturity date of the Third Amended and Restated Revolvin

Pro-Dex, Inc. Announces Fiscal 2027 First Quarter Results

IRVINE, CA / ACCESS Newswire / October 29, 2026 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2027 first quarter ended September 30, 2026. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2027 with the Securities and Exchange Commission today.

Quarter Ended September 30, 2026

Net sales for the three months ended September 30, 2026, increased $2.1 million, or 11%, to $20.6 million from $18.5 million for the three months ended September 30, 2025. The increase is driven primarily by a $3.3 million increase in medical device revenue, inclusive of rebates, of which $1.8 million relates to the next-generation handpiece we sell to our largest customer, offset by a $1.7 million decrease in repairs of the legacy handpiece we sell to that customer, coupled with an increase in revenue of $511,000 generated by the Company's newly acquired subsidiary, Advanced Precision Machining, LLC ("APM"), exclusive of inter-company sales in the amount of $814,000 which are eliminated in consolidation.

Gross profit for the three months ended September 30, 2026, increased $1.5 million, or 28%, compared to the year-ago period. Gross margin increased by 4 percentage points to 33% during the three months ended September 30, 2026, compared to 29% during the corresponding year-ago period, due primarily as a result of favorable product mix.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2026, increased $1.1 million, or 48%, to $3.3 million compared to $2.3 million for the prior fiscal year's corresponding quarter. The increase relates to a $442,000 increase in engineering and a $642,000 increase in selling, general and administrative expenses. The increase in engineering relates to personnel costs as well as higher internal project expenditures. The increase in selling, general and administrative expense is primarily due to $466,000 of APM's separate operations as well as $195,000 of higher personnel costs specifically related to accounting, mergers and acquisitions, human resources, and information technology.

Our operating income for the quarter ended September 30, 2026, increased $406,000, or 13%, to $3.5 million compared to $3.1 million for the prior fiscal year's corresponding quarter. The increase reflects our increased gross profit, offset by our increased operating expenses, as described above.

Net income for the quarter ended September 30, 2026, decreased to $3.0 million, or $0.92 per diluted share, compared to net income of $4.7 million, or $1.40 per diluted share, for the quarter ended September 30, 2025. Our net income for the quarter ended September 30, 2026, contains unrealized gains on our marketable equity investments of $73,000, while our net income for the quarter ended September 30, 2025, includes unrealized gains on our marketable equity investments of $3.3 million. All of our investments are recorded at estimated fair value, and the period-to-period valuation can be highly volatile. For example, our investment in Monogram Technologies, Inc. was valued as of September 30, 2025 at the cash price we received in October 2025, upon its acquisition by Zimmer Biomet Holdings, Inc. We received $4.04 per share for each of the common shares we owned of Monogram, for a total of $8.9 million in cash proceeds.

CEO Comments

Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our first quarter results and continued top line revenue growth." Mr. Van Kirk concluded, "We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year."

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the aerospace and defense industries in addition to providing several machined components to support Pro-Dex's customers. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's websites at www.pro-dex.com and www.advanced-precision.com .

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance (including the expected shipment of Monogram validation units) as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the risk factors and other disclosures concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

On October 26, 2026, Advanced Precision Machining, LLC (“APM”), a wholly owned subsidiary of Pro-Dex, Inc. (the “Company”), entered into three Standard Lease Renewal Forms (the “Lease Renewals”) with Trico Costa Mesa Properties, L.P., a California limited partnership. The Lease Renewals amend the existing lease agreements, as previously amended (the “Leases”), covering approximately 2,500 square feet of office and industrial space located at 1645, 1647 and 1649 Monrovia Avenue, Costa Mesa, California, which collectively comprise APM’s office, manufacturing and warehouse space.

The Lease Renewals extend the term of the Leases to September 30, 2030, and beginning on February 1, 2027, implement base rent increases ranging from 4.0% to 6.6%. As result, for each of space 1647 and 1649, the base rent is $5,651 per month from February 1, 2027 through October 31, 2028, and increases by 4.0%, or $227 per month, on November 1, 2028 through September 30, 2030. For space 1645, the base rent is $5,513 per month from February 1, 2027 through October 31, 2028, and increases by 6.6%, or $365 per month, on November 1, 2028 through September 30, 2030.

Prompts

Pro-Dex, Inc. (ticker PDEX), listed in United States.

ETFs Holding Pro-Dex, Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.16% 766 $ 44.849K Jun 30, 2026
DFAS 0.01% 29,920 $ 2.017M Nov 12, 2026
DFSU 0.00% 643 $ 43.351K Nov 12, 2026
DXUV 0.00% 1,538 $ 103.692K Nov 12, 2026
DCOR 0.00% 5,186 $ 349.64K Nov 12, 2026
DFAC 0.00% 8,419 $ 567.609K Nov 12, 2026
DFUS 0.00% 344 $ 23.192K Nov 12, 2026
AVSC 0.00% 2,205 $ 142.178K Nov 16, 2026